Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World Study.

Summary

High-throughput in vitro testing showed that 84% (518/620) of rare CFTR variants responded to elexacaftor/tezacaftor/ivacaftor. In a 24-week randomized, placebo-controlled phase 3 trial, ETI improved ppFEV1 (+9.2 points), reduced sweat chloride (−28.3 mmol/L), and improved CFQ-R respiratory scores; real‑world data corroborated lung function gains. Findings support extending ETI to people with rare CFTR variants without F508del.

Key Findings

• 84% (518/620) of rare exonic CFTR variants demonstrated in vitro response to elexacaftor/tezacaftor/ivacaftor.
• Phase 3 RCT (24 weeks) showed ppFEV1 improvement of +9.2 percentage points, sweat chloride reduction of −28.3 mmol/L, and CFQ‑R respiratory domain increase of +19.5 points versus placebo.
• Real‑world study (82 variants) showed lung function improvements after ETI initiation, supporting external validity.

Clinical Implications

Regulators and clinicians can leverage in vitro responsiveness plus confirmatory clinical data to grant access to ETI for patients with rare CFTR variants, with expected improvements in lung function and quality of life.

Limitations

• Small per‑variant clinical sample sizes limit precision for individual rare alleles
• Durability and safety beyond 24 weeks for specific variants require longer follow‑up

Future Directions

Expand regulatory frameworks to accept validated in vitro responsiveness for label extension; conduct long‑term safety/effectiveness registries for rare variants and head‑to‑head comparisons among modulators.